- cafead Dec 09, 2020 at 11:12: AM
via Novartis already knew that adding Kisqali to endocrine therapy can help premenopausal patients with HR-positive, HER2-negative advanced breast cancer live longer. Now, it knows exactly how long.
Kisqali plus endocrine therapy helped pre- and perimenopausal women with HR+/HER2- disease live a median 58.7 months, according to phase 3 data presented at the San Antonio Breast Cancer Symposium's (SABCS') virtual annual meeting. That’s compared with 48 months for endocrine therapy alone, translating to a 24% reduction in the risk of death for the Kisqali regimen.
article source
Kisqali plus endocrine therapy helped pre- and perimenopausal women with HR+/HER2- disease live a median 58.7 months, according to phase 3 data presented at the San Antonio Breast Cancer Symposium's (SABCS') virtual annual meeting. That’s compared with 48 months for endocrine therapy alone, translating to a 24% reduction in the risk of death for the Kisqali regimen.
article source